Allakos Investor Relations Material

Allakos Inc. is a biopharmaceutical company focused on the development of antibody-based therapies for the treatment of allergic, inflammatory, and proliferative diseases. The company's primary approach involves targeting specific immune cells and inflammatory pathways that contribute to diseases such as eosinophilic gastritis and other related gastrointestinal and inflammatory conditions. Allakos leverages proprietary antibody technologies to create potential therapeutic options aimed at improving outcomes for patients with limited treatment choices. The company is headquartered in San Carlos, California, and its shares are listed on the NASDAQ.